IRLAB Therapeutics is focused on developing novel, potential first-in-class treatments for the symptoms of PD and other central nervous system (CNS) disorders. Its proprietary ISP discovery platform has been validated by the progress of its two lead assets, pirepemat and mesdopetam, which have novel mechanisms of action. Pirepemat is an oral prefrontal cortex enhancer in a Phase IIb trial for the treatment of impaired balance and falls in PD. Mesdopetam, an oral D3 antagonist, failed to hit primary endpoints in a Phase IIb trial for levodopa-induced dyskinesias in January 2023; however, the study did meet a key secondary efficacy endpoint. IRLAB has licensed the global rights for mesdopetam to Ipsen and we await further communication on how this data will define Ipsen’s future development strategy for the drug. IRLAB is also developing three preclinical assets, IRL942, IRL757 and IRL117 for various CNS indications. The company remains well funded in the medium term.